Terran Biosciences, a pioneering force in the psychedelic therapeutic space, has recently achieved a significant milestone. The United States Patent and Trademark Office (USPTO) has granted notice of allowance for four US patents under Terran’s banner. These patents are not just a testament to Terran’s innovative approach but also mark a new era in psychedelic therapy, covering new forms of psilocybin, orally active DMT, 5-MeO-DMT, and novel ibogaine derivatives.
New Forms of Psilocybin: A Leap Forward in Neurological and Psychiatric Treatment
Two of Terran’s patents are particularly noteworthy as they cover the world’s first new forms of psilocybin – psilocybin HCl and psilocybin edisylate. These new forms, along with their methods of use, are poised to revolutionize the treatment of neurological and psychiatric disorders, including depression. Historically, clinical trials of psilocybin have been limited to older forms of the compound. Terran’s breakthroughs promise to expand the horizons of psilocybin therapy significantly.
Moreover, Terran is strategically positioned to pursue a rapid 505(b)(2) FDA approval pathway for its new psilocybin forms. This pathway could be a game-changer, allowing Terran to use pharmacokinetic bridging studies and existing safety and efficacy data to expedite the process of bringing a Terran psilocybin product to market.
Orally Active DMT and 5-MeO-DMT: Simplifying Administration
Another groundbreaking achievement by Terran is the development of the world’s first orally active prodrugs of DMT and 5-MeO-DMT. Traditionally, DMT requires combination with a monoamine oxidase inhibitor (MAOI) for oral activity, a method fraught with side effects like nausea and blood pressure changes. Terran’s new prodrugs circumvent these challenges, offering a single oral dose option without the need for an MAOI.
Novel Ibogaine Derivative: Tabernanthalog Monofumarate
Terran’s innovation extends to the development of ibogaine derivatives. The company has received a notice of allowance for a novel form of tabernanthalog monofumarate, which shows promise in treating neurological and psychiatric disorders. This discovery could represent the most stable form of tabernanthalog monofumarate to date.
Terran Biosciences is not just innovating; it’s redefining the landscape of psychedelic therapeutics. With these new patents, Terran is poised to offer more effective, accessible, and convenient treatment options for patients suffering from various neurological and psychiatric disorders. The future of psychedelic therapy is bright, and Terran Biosciences is leading the charge.
